Novelties in Research and Treatments of Pancreatic Cancers

Speaker: Thomas Seufferlein

T. Seufferlein provides molecular insights in the biology of pancreatic cancer which opens-up opportunities for testing already existing and new drugs. He explains the results from the study with novel immunotherapeutic agent IMM 101; the study allowed recruitment of patients with WHO PS 2, the real-life population - less ideal one from usual clinical trial situation. Therefore, the results achieved are even more important. Furthermore, he elaborates the results from the study with PEGPH20, an agent with novel mechanism of action and digs into other new agents/strategies on horizon in this setting.

Discussion Points

  • Biology of pancreatic cancers
  • What is a mechanism of action of novel drugs IMM 101 and PEGPH20?
  • Results from a phase II trial of gemcitabine with and without IMM 101 in advanced pancreatic cancer (abstract O-0003)
  • Results from a phase II trial of PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumours (abstract LBA-02)
  • Other new agents/strategies on the horizon for pancreatic cancer